Brokers

Brokers Set Expectations for Viridian Therapeutics, Inc.’s Q2 2022 Earnings (NASDAQ:VRDN)


Viridian Therapeutics, Inc. (NASDAQ:VRDNGet Rating) – Equities researchers at B. Riley issued their Q2 2022 earnings per share (EPS) estimates for Viridian Therapeutics in a research report issued on Thursday, June 23rd. B. Riley analyst K. Patel anticipates that the company will post earnings per share of ($1.01) for the quarter. B. Riley currently has a “Buy” rating and a $25.00 target price on the stock. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.75) per share. B. Riley also issued estimates for Viridian Therapeutics’ Q3 2022 earnings at ($1.01) EPS, Q4 2022 earnings at ($1.05) EPS, FY2023 earnings at ($3.64) EPS, FY2024 earnings at ($3.21) EPS and FY2025 earnings at ($3.26) EPS.

Viridian Therapeutics (NASDAQ:VRDNGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.06). The company had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.65 million. Viridian Therapeutics had a negative return on equity of 360.68% and a negative net margin of 5,014.24%.

Separately, JMP Securities decreased their price target on Viridian Therapeutics from $36.00 to $31.00 and set a “market outperform” rating on the stock in a research note on Friday, March 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Viridian Therapeutics has a consensus rating of “Buy” and a consensus price target of $32.80.

Shares of NASDAQ:VRDN opened at $10.97 on Friday. The stock’s 50-day moving average price is $12.54 and its two-hundred day moving average price is $17.00. Viridian Therapeutics has a 12-month low of $9.47 and a 12-month high of $22.00. The firm has a market cap of $306.36 million, a price-to-earnings ratio of -1.90 and a beta of 1.13.

In other Viridian Therapeutics news, CEO Jonathan Violin sold 30,000 shares of Viridian Therapeutics stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $13.04, for a total transaction of $391,200.00. Following the sale, the chief executive officer now directly owns 510,905 shares in the company, valued at approximately $6,662,201.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 90,000 shares of company stock worth $1,324,836 over the last 90 days. 4.48% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. acquired a new position in Viridian Therapeutics during the 1st quarter valued at approximately $32,164,000. Deep Track Capital LP acquired a new position in Viridian Therapeutics during the 4th quarter valued at approximately $26,426,000. TCG Crossover Management LLC acquired a new position in Viridian Therapeutics during the 4th quarter valued at approximately $25,978,000. Citadel Advisors LLC acquired a new position in Viridian Therapeutics during the 4th quarter valued at approximately $18,650,000. Finally, Perceptive Advisors LLC boosted its position in Viridian Therapeutics by 79.1% during the 3rd quarter. Perceptive Advisors LLC now owns 1,423,000 shares of the company’s stock valued at $23,408,000 after purchasing an additional 628,494 shares during the period.

About Viridian Therapeutics (Get Rating)

Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.

Read More

Earnings History and Estimates for Viridian Therapeutics (NASDAQ:VRDN)



Receive News & Ratings for Viridian Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Viridian Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.